Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
S&P Biotech SPDR
(NY:
XBI
)
101.51
+1.37 (+1.37%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about S&P Biotech SPDR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
US Judge Weighs Nationwide Ban On Abortion Pills
March 16, 2023
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...
Via
Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Biotech Stocks And The SVB Collapse — Here's What We Know
March 14, 2023
The collapse of SVB will have a big impact on early-stage, venture-backed companies.
Via
Investor's Business Daily
Silicon Valley Bank Meltdown Hits Healthcare Sector As Well
March 13, 2023
The Federal Deposit Insurance Corporation (FDIC) closed Silicon Valley Bank, the banking arm of SVB Financial Group (NASDAQ:
Via
Benzinga
Small Cap Biotechs Slammed By SVB Collapse
March 13, 2023
Nothing like a banking crisis to start off a weekend. But maybe by the end of this upcoming week of turmoil we'll worry less about inflation.
Via
Talk Markets
6 Stock Market Thoughts For The Week Of March 13
March 12, 2023
A flight to safety seemed to be at play this week, with the market seeking safety first and asking questions later. This is not unusual, and once the situation is resolved, much of the decline in rates...
Via
Talk Markets
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
March 10, 2023
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...
Via
Benzinga
FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities
March 10, 2023
Via
Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
March 06, 2023
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.
Via
Talk Markets
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
March 01, 2023
Via
Benzinga
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Via
Talk Markets
Stryker, DaVita And These 2 ETFs: CNBC's 'Final Trades'
January 31, 2023
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named the SPDR S&P Biotech ETF (NYSE: XBI), saying if you "want growth,
Via
Benzinga
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
January 30, 2023
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.
Via
Talk Markets
2 ETFs That Can Set You Up for Life
January 25, 2023
Simplifying your investment strategy can help minimize your risk while still allowing you to earn some great returns.
Via
The Motley Fool
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
January 23, 2023
The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength.
Via
Talk Markets
The Fed Should Stop Right Now
January 19, 2023
A pause to refresh or a mild pullback would be good for the stock market after running hot and heavy. On Wednesday, we saw weaker economic data in retail sales. Unlike previous soft data, the stock...
Via
Talk Markets
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
January 17, 2023
Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing.
Via
Talk Markets
Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing”
January 12, 2023
Small-cap speculative biotech stocks regain interest with volatility.
Via
Talk Markets
3 Unstoppable ETFs to Stock Up On in 2023
January 09, 2023
These ETFs could be big winners in the new year.
Via
The Motley Fool
ETFs To Buy For 2023 After S&P 500's Worst Year Since 2008
January 08, 2023
The S&P 500 has dropped 19.4% in 2022. It marked the largest calendar-year decline since a 38% plunge in Lehman Bother’s crisis-laden 2008. Goldman Sachs, Bank of America and JPMorgan predict a U.S....
Via
Talk Markets
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
5 Top Stocks for January
January 01, 2023
Now is the time to begin crafting your watch list for 2023.
Via
The Motley Fool
The Year In Review And Ahead
December 29, 2022
We‘ll continue witnessing cost-push inflation combined with tight labor market – and it would be crude oil‘s time again to gain in value from current levels.
Via
Talk Markets
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
December 25, 2022
These mid-cap biotechs are solid long-term choices.
Via
The Motley Fool
Tuesday Talk: Where is Santa?
December 20, 2022
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found.
Via
Talk Markets
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
December 19, 2022
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.
Via
Talk Markets
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
December 18, 2022
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year.
Via
InvestorPlace
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Via
Benzinga
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead
November 28, 2022
Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.
Via
Talk Markets
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.